| Previous close | 17.10 |
| Open | 17.10 |
| Bid | 18.10 |
| Ask | 18.70 |
| Strike | 77.50 |
| Expiry date | 2024-01-19 |
| Day's range | 17.10 - 17.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 871 |
- Zacks
Novartis' (NVS) PNH Candidate Achieves Study Objectives
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
- GlobeNewswire
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)1Topline APPOINT-PNH data were consistent with APPLY-PNH readout and showed a significant proportion of complement-inhibitor-naïve patients treated with iptacopan achieved clinically meaningful increases in hemoglobin levels vs. baseline without the need for blood transfusions1PNH has a significant
- Zacks
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
